Cost-utility analysis of ceftazidime-avibactam versus colistin-meropenem in the treatment of infections due to Carbapenem-resistant Klebsiella pneumoniae in Colombia-Reference-Cited by-同舟云学术

Cost-utility analysis of ceftazidime-avibactam versus colistin-meropenem in the treatment of infections due to Carbapenem-resistant Klebsiella pneumoniae in Colombia

Published:2021-08-18 Issue: Volume: Page:1-6
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Varón-Vega FA¹²,Lemos E³,Castaño Gamboa N⁴^ORCID,Reyes JM⁴^ORCID

Affiliation:

1. Universidad de Navarra, Research Deparment, Pamplona, España

2. Fundación Neumológica Colombiana, Research Deparment, Bogotá, Colombia

3. Pfizer SAS, Hospitals Medical, Bogotá, Colombia

4. Pfizer SAS, Health Outcomes, Bogotá, Colombia

Funder

Pfizer S.A.S

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2021.1964960

Reference38 articles.

1. National Center for Emerging and Zoonotic Infectious Diseases/Centers for Disease Control and Prevention (CDC). Facility guidance for control of carbapenem-resistant enterobacteriaceae (CRE). 2015.

2. Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections

3. Current Concepts in Antimicrobial Therapy Against Resistant Gram-Negative Organisms: Extended-Spectrum β-Lactamase–Producing Enterobacteriaceae, Carbapenem-Resistant Enterobacteriaceae, and Multidrug-Resistant Pseudomonas aeruginosa

4. Appropriate initial antibiotic therapy in hospitalized patients with gram-negative infections: systematic review and meta-analysis

5. The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Costs-effectiveness and cost components of pharmaceutical and non-pharmaceutical interventions affecting antibiotic resistance outcomes in hospital patients: a systematic literature review;BMJ Global Health;2024-02

2. Real-world effectiveness of ceftazidime/avibactam versus polymyxin B in treating patients with carbapenem-resistant Gram-negative bacterial infections;International Journal of Antimicrobial Agents;2023-08

3. Cost-effectiveness analysis of ceftazidime avibactam versus colistin in carbapenem-resistant enterobacteriaceae in Iran;Cost Effectiveness and Resource Allocation;2023-07-24

4. A review of economic studies evaluating the treatment of ventilator associated pneumonia;2023-03-27

5. In vitro activity of ceftazidime/avibactam against Gram-negative strains in Colombia 2014–2018;Journal of Global Antimicrobial Resistance;2022-06